Form 4: BioLife Solutions Director Amy DuRoss Reports Stock Sale and Acquisition

Director Amy DuRoss reports selling shares of BioLife Solutions under a 10b5-1 trading plan and acquiring restricted stock.

Summary

• On March 14, 2025, Amy DuRoss, a director of BioLife Solutions Inc., sold 5,632 shares of common stock at a weighted average price of $24.96.
• The sales were executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on December 13, 2024.
• On March 18, 2025, DuRoss acquired 6,876 shares of restricted stock.
• These shares were granted under the BioLife Solutions 2023 Performance Incentive Plan and will fully vest on January 2, 2026, which is the first anniversary of the measurement date of January 2, 2025.
• Following these transactions, DuRoss directly owns 30,687 shares of BioLife Solutions common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as the document primarily reports routine insider transactions. The sale is under a pre-arranged plan, and the acquisition of restricted stock is a positive sign.

Positives

• The acquisition of restricted stock demonstrates continued alignment with the company's long-term performance.

Negatives

• The sale of shares, even under a pre-arranged plan, could be perceived negatively by some investors.

Risks

• The market's reaction to insider selling, even if pre-planned, can be unpredictable.

Future Outlook

Not explicitly stated, but the vesting of restricted stock in 2026 suggests a continued involvement and alignment with the company's future performance.

Industry Context

Insider transactions are common and closely watched in the biotech industry. Sales under 10b5-1 plans are generally viewed as less concerning than discretionary sales.

Comparison to Industry Standards

• Monitoring insider transactions is a standard practice in the biotech industry, with firms like Thermo Fisher Scientific and Danaher also seeing regular Form 4 filings.
• The use of 10b5-1 trading plans is a common strategy among executives in publicly traded companies to avoid accusations of insider trading.

Stakeholder Impact

• Shareholders may react to the stock sale, although it is under a pre-arranged plan.
• The acquisition of restricted stock could reassure stakeholders about the director's commitment to the company.

Key Dates

Keywords

BioLife Solutions, BLFS, Amy DuRoss, insider trading, Form 4, stock sale, restricted stock, Rule 10b5-1, director